Extended Data Fig. 5: Refined mutation–mutation interactions analysis for specific mutations targeted by therapies. | Nature Medicine

Extended Data Fig. 5: Refined mutation–mutation interactions analysis for specific mutations targeted by therapies.

From: Systematic pan-cancer analysis of mutation–treatment interactions using large real-world clinicogenomics data

Extended Data Fig. 5

Anchor genes and modifier genes are selected in the same way as in Fig. 3. For each anchor gene, we only consider mutations subtypes that are specifically focused on by FDA-approved targeted therapies (written below the gene name). The size of a modifier gene’s circle indicates what fraction of patients with the anchor gene mutated in the pathogenic subtypes also have mutation in the modifier gene. The modifier’s color indicates its positive (blue for HR <1) or negative (red for HR >1) impact on the survival of patients who have the anchor gene pathogenic mutation. Modifiers are genes with significant anchor-modifier interactions (two-sided Wald test P value <0.05).

Back to article page